Japanese startup Craif raised $22 million in Series C funding. The company develops AI-powered, non-invasive early cancer detection using urine-based microRNA analysis.
Craif plans to expand into the U.S. market and advance research. The round was led by X&KSK and included the U.S. investor Unreasonable Group, TAUNS Laboratories, Daiwa House Industry, and Aozora Bank Group.
Innovative Approach to Early Cancer Detection
Founded by CEO Ryuichi Onose and Associate Professor Takao Yasui, Craif uses microRNA, a biomarker secreted by early cancer cells, to identify cancers at very early stages. Their test is non-invasive and can be done at home, improving accessibility.
Cancer remains a leading cause of death worldwide, with nearly 20 million new cases and 9.7 million deaths reported in 2022. New cases could reach 29.9 million by 2040, highlighting the need for accessible early detection. The National Cancer Institute figures show the urgency.
Technology and Market Expansion
Craif’s technology analyzes urinary microRNA, offering advantages over common blood-based tests. Urine samples reduce impurities, lowering measurement errors and costs. The company targets seven cancer types, including pancreatic and breast cancer, with plans to expand to ten.
The company generated $5 million in 2024 revenue, aims for $15 million in 2025, and serves about 20,000 users through over 1,000 clinics and 600 pharmacies in Japan. The startup also plans trials in the U.S., seeking FDA approval by around 2029.
- Total funding raised: $57 million
- Post-Series C valuation: nearly $100 million
- U.S. offices in Irvine and upcoming San Diego location
Craif competes in a growing AI-driven early cancer detection field alongside startups like Grail, Freenome, and DELFI Diagnostics.
The recent recognition of microRNA’s role in cancer biology, including links to the 2024 Nobel Prize, supports Craif’s scientific approach. This reinforces the potential impact of their urine-based test in early cancer diagnosis.
Looking Ahead
Craif plans to broaden its product scope beyond cancer to include non-cancer diseases like dementia. The Series C funding will accelerate its U.S. entry and research development.
More details about Craif’s work and expansion can be found on the company’s official site Craif.
Leave a Reply